FDA Off-Label Policy Under Fire: Court Rulings Pile Up, House E&C Floats New Bill
Executive Summary
Republican leadership on the House Energy and Commerce Committee is reviving efforts to legislate changes to FDA’s off-label policy. That renewed pressure comes as the courts are increasingly challenging FDA’s ability to bar truthful speech about unapproved indications.